Summit Therapeutics SMMT Business Segments — Operating Expenses

Similar metrics at other companies

BBIOReportable Segment Aggregation Before Other Operating — Total Costs & Expenses

$244.84M+37.8%

SOReportable Segment — Operational expenses

$64M+12.3%

BBIOReportable Segment — Costs and Expenses

$300.47M+36.0%

OMCReportable Segment — Costs and Expenses

$5.5B+71.6%

JLLReportable Subsegments — Operating Expenses

$713M+3.5%

RDDTReportable Segment — Operating expenses

$424.23M+20.7%

Questions, answered.

What is Summit Therapeutics's business segments — operating expenses?

Summit Therapeutics (SMMT) reported business segments — operating expenses of $195.21M in Q1 2026.

How has Summit Therapeutics's business segments — operating expenses changed year-over-year?

Summit Therapeutics's business segments — operating expenses increased by 192.0% year-over-year, from $66.85M to $195.21M.

What is the long-term trend for Summit Therapeutics's business segments — operating expenses?

Over 3 years (2022 to 2025), Summit Therapeutics's business segments — operating expenses has grown at a 132.4% compound annual growth rate (CAGR), from $87.21M to $1.09B.

What does business segments — operating expenses mean?

The total cost of running the business segment during the period.

How do you interpret business segments — operating expenses?

Increasing expenses are expected for growth-stage biotech firms, but sustained growth without revenue milestones may signal liquidity risk.

How does business segments — operating expenses compare across companies?

Standard metric for all public companies; essential for calculating operating margins and cash runway.